Current Status: Active PolicyStat ID: 10442280

**Beaumont** 

 Origination:
 2/14/2022

 Effective:
 2/14/2022

 Last Approved:
 2/14/2022

 Last Revised:
 2/14/2022

 Next Review:
 2/14/2024

**Document Contact:** *Michele Sedlak: Medical* 

Technologist Lead

Area: Laboratory-Hematology

**Key Words:** 

Applicability: All Beaumont Hospitals

# Smears Left for Pathologist Review and Cases Requiring Stat Review

Document Type: Guideline

# I. PURPOSE AND OBJECTIVE:

To verify that new acute leukemias/ newly identified blasts identified by the technologist on peripheral smear are reviewed/ finalized by hematopathologist/ pathologist in a timely fashion, specifically reviewed at least daily (less than 24 hours) and not held. Also, to delineate cases that may require stat delivery from sites without a hematopathologist.

# II. ACRONYMS:

- A. Complete Blood Count (CBC)
- B. Laboratory Information System (LIS)

# III. PERFORMED BY:

- A. Technologist reviewing smear
- B. Hematopathologist/ pathologist

### IV. EXPECTED PERFORMANCE:

It is expected that this workflow will ensure that patient results are reported in a timely fashion, i.e. CBC and differential results are not held because first time blasts are identified.

# V. STAT REVIEW CRITERIA:

- A. Suspect acute leukemia cases.
- B. Suspect Acute Promyelocytic Leukemia (APL) cases.
- C. Any blasts or unknown cells more than rare or few.
- D. Suspect Thrombotic thrombocytopenic purpura (TTP) cases (i.e. schistocytes, especially in unexplained anemia and thrombocytopenia).
- E. Physician request cases suspecting leukemia.

# VI. RESPONSIBILITY:

#### A. Technologist Responsibility:

- 1. Report differential per procedure. (Refer to Path Review Workflow-RO for appropriate steps).
- 2. Notify pathologist, following site-specific directives.
  - a. Transfer slide and paperwork to the pathologist review site (as applicable).
  - b. Notify the laboratory site the slide and paperwork are to be transferred to (as applicable).

#### B. Pathologist Responsibility:

- 1. Review case results.
- 2. Finalize case in LIS (i.e. pathologist comment).
- 3. Notify clinician.

# **VII. QUALITY CONTROL:**

Lab Manager, Hematology Laboratory

# VIII. NOTES:

- A. It will be left to the discretion of the hematopathologist/pathologist at site how they prefer such cases to be communicated to them (e.g. resident/pathologist on-call, image(s) delivered via email, etc.); however, it is imperative that such cases be reported out within 24 hours and CBC and differential results are not held.
- B. To prevent delay in treatment, prompt communication with clinician is critical.

#### **Attachments**

No Attachments

# **Approval Signatures**

Step Description	Approver	Date
	Vaishali Pansare: Chief, Pathology	2/14/2022
	Jeremy Powers: Chief, Pathology	2/8/2022
	Muhammad Arshad: Chief, Pathology	2/4/2022
	John Pui: Chief, Pathology	2/4/2022
	Ann Marie Blenc: System Med Dir, Hematopath	2/4/2022
Hematology Medical Director Designee	Ann Marie Blenc: System Med Dir, Hematopath	2/4/2022
Policy and Forms Steering Committee Approval (if needed)	Michele Sedlak: Medical Technologist Lead	2/3/2022
Policy and Forms Steering Committee	Gail Juleff: Project Mgr Policy	1/21/2022

Step Description	Approver	Date
Approval (if needed)		
System Operations Director	Brittnie Berger: Dir, Lab Operations C	1/11/2022
	Megan Masakowski: Medical Technologist	1/5/2022
	Michele Sedlak: Medical Technologist Lead	12/17/2021

# **Applicability**

Dearborn, Farmington Hills, Grosse Pointe, Royal Oak, Taylor, Trenton, Troy, Wayne

